Watkins Rachel J, Imruetaicharoenchoke Waraporn, Read Martin L, Sharma Neil, Poole Vikki L, Gentilin Erica, Bansal Sukhchain, Bosseboeuf Emy, Fletcher Rachel, Nieto Hannah R, Mallick Ujjal, Hackshaw Allan, Mehanna Hisham, Boelaert Kristien, Smith Vicki E, McCabe Christopher J
Institute of Metabolism and Systems Research (R.J.W., W.I., M.L.R., N.S., V.L.P., S.B., R.F., H.R.N., K.B., V.E.S., C.J.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom; Department of Surgery, Faculty of Medicine (W.I.), Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; Section of Endocrinology and Internal Medicine (E.G.), University of Ferrara, 44121 Ferrara, Italy; STIM Laboratory (E.B.), University of Poitiers, 86073 Poitiers Cedex 9, France; Northern Centre for Cancer Care (U.M.), Freeman Hospital, Newcastle upon Tyne NE7 7DN, United Kingdom; Cancer Research United Kingdom & UCL Cancer Trials Centre (A.H.), University College London, London WC1E 6BT, United Kingdom; and Institute of Cancer and Genomic Sciences (H.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom.
J Clin Endocrinol Metab. 2016 Dec;101(12):4551-4563. doi: 10.1210/jc.2016-1932. Epub 2016 Sep 7.
Metastatic disease is responsible for the majority of endocrine cancer deaths. New therapeutic targets are urgently needed to improve patient survival rates.
The proto-oncogene PTTG1-binding factor (PBF/PTTG1IP) is overexpressed in multiple endocrine cancers and circumstantially associated with tumor aggressiveness. This study aimed to understand the role of PBF in tumor cell invasion and identify possible routes to inhibit its action. Design, Setting, Patients, and Interventions: Thyroid, breast, and colorectal cells were transfected with PBF and cultured for in vitro analysis. PBF and cortactin (CTTN) expression was determined in differentiated thyroid cancer and The Cancer Genome Atlas RNA-seq data.
Pro-invasive effects of PBF were evaluated by 2D Boyden chamber, 3D organotypic, and proximity ligation assays.
Our study identified that PBF and CTTN physically interact and co-localize, and that this occurs at the cell periphery, particularly at the leading edge of migrating cancer cells. Critically, PBF induces potent cellular invasion and migration in thyroid and breast cancer cells, which is entirely abrogated in the absence of CTTN. Importantly, we found that CTTN is over-expressed in differentiated thyroid cancer, particularly in patients with regional lymph node metastasis, which significantly correlates with elevated PBF expression. Mutation of PBF (Y174A) or pharmacological intervention modulates the PBF: CTTN interaction and attenuates the invasive properties of cancer cells.
Our results demonstrate a unique role for PBF in regulating CTTN function to promote endocrine cell invasion and migration, as well as identify a new targetable interaction to block tumor cell movement.
转移性疾病是大多数内分泌癌死亡的原因。迫切需要新的治疗靶点来提高患者生存率。
原癌基因PTTG1结合因子(PBF/PTTG1IP)在多种内分泌癌中过表达,并与肿瘤侵袭性存在间接关联。本研究旨在了解PBF在肿瘤细胞侵袭中的作用,并确定抑制其作用的可能途径。设计、地点、患者和干预措施:用PBF转染甲状腺、乳腺和结肠直肠细胞,并进行体外培养分析。在分化型甲状腺癌和癌症基因组图谱RNA测序数据中测定PBF和皮质肌动蛋白(CTTN)的表达。
通过二维博伊登小室、三维器官型和邻近连接分析评估PBF的促侵袭作用。
我们的研究发现PBF和CTTN发生物理相互作用并共定位,且这种情况发生在细胞周边,尤其是在迁移癌细胞的前沿。至关重要的是,PBF在甲状腺和乳腺癌细胞中诱导强烈的细胞侵袭和迁移,而在没有CTTN的情况下这种作用完全消除。重要的是,我们发现CTTN在分化型甲状腺癌中过表达,尤其是在有区域淋巴结转移的患者中,这与PBF表达升高显著相关。PBF(Y174A)突变或药物干预可调节PBF与CTTN的相互作用,并减弱癌细胞的侵袭特性。
我们的结果证明了PBF在调节CTTN功能以促进内分泌细胞侵袭和迁移方面具有独特作用,同时还确定了一个可靶向的新相互作用来阻断肿瘤细胞的移动。